Key result
In elderly Chinese patients with acute coronary syndrome, half-loading dose ticagrelor did not reduce the 90-day composite endpoint of death, myocardial infarction, or stroke compared to clopidogrel.
Why the study?
The study was conducted to evaluate the effects of half-load doses of ticagrelor versus clopidogrel in elderly acute coronary syndrome patients over 90 days.
Does a half loading dose of ticagrelor improve clinical outcomes compared to clopidogrel in elderly patients with acute coronary syndrome?
RCT (n=74)
Single-blind
Randomized
No
Does a half loading dose of ticagrelor improve clinical outcomes compared to clopidogrel in elderly patients with acute coronary syndrome?
A half loading dose of ticagrelor (90 mg) did not demonstrate a considerable difference in therapeutic benefit compared to a 300 mg loading dose of clopidogrel in elderly patients with acute coronary syndrome.
Answers are grounded in this paper and cite their sources.
Half-load ticagrelor may be feasible in elderly ACS; hypothesis-generating and requires validation in larger trials.
Purpose: To evaluate the effects of half-load doses (HLD) of ticagrelor and clopidogrel on elderly acute coronary syndrome patients (ACS) over a period of 90 days. Methods: Seventy-four patients diagnosed as ACS were included in this trial. The patients were randomly distributed into group 1 (treated with HLD ticagrelor, 90 mg LD) and group 2 (treated with clopidogrel, 300 mg LD). The interaction of treatment effect was evaluated using Multivariate Cox proportional hazards regression models. Results: Within three months, a total of 12 patients (16.21 %) died of myocardial infarction or stroke. The endpoint of HLD ticagrelor-treated elderly ACS patients was 20 %, and the incidence of clopidogreltreated endpoints was 14.81 %. Conclusion: In the first 45 patients treated with HLD ticagrelor, their cumulative incidence of cardiac events was relatively high. However, there were no considerable changes in the therapeutic benefits of these two drugs in elderly ACS patients.
No takes yet. Share an insight, caveat, or question.
Xue et al. (2020) conducted an RCT in Acute coronary syndrome (n=74). Ticagrelor vs. Clopidogrel (300 mg loading dose, then 75 mg daily) was evaluated on Composite of death, myocardial infarction recurrence, or stroke at 90 days. In elderly Chinese patients with acute coronary syndrome, half-loading dose ticagrelor did not reduce the 90-day composite endpoint of death, myocardial infarction, or stroke compared to clopidogrel.
Synapse has enriched 10 related papers. Consider them for comparative context: